{
    "clinical_study": {
        "@rank": "98976", 
        "arm_group": [
            {
                "arm_group_label": "females with medical history of repeated foetal losses", 
                "description": "The females can be pregnant"
            }, 
            {
                "arm_group_label": "females without medical history of repeated foetal losses", 
                "description": "The females can be pregnant"
            }
        ], 
        "biospec_descr": {
            "textblock": "blood samples"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "The aim of the study is to assess the role of complement dysregulation and its impact on\n      antiangiogenic factors (soluble Flt1 and endoglin) in patients with foetal losses."
        }, 
        "brief_title": "Multicentric Prospective Study of Genetic and Physiopathology Concerning Dysregulation of Complement During Repeated Fetal Abortions", 
        "condition": "Fetal Losses", 
        "detailed_description": {
            "textblock": "Females with medical history of repeated foetal losses will have blood sampling to perform\n      analyses. If pregnant, blood sampling will be performed at different times throughout the\n      pregnancy.\n\n      Controls will be females without medical history of repeated foetal losses. They will also\n      have blood sampling to perform analyses. If pregnant, blood sampling will be performed  at\n      different times throughout the pregnancy.\n\n      Blood analyses will focus on :\n\n        -  mutations in genes coding for molecules that modulate complement activity\n\n        -  serum levels of sFlt1 and endoglin and their link to complement activation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Inclusion criteria for females with repeated fetal losses:\n\n          -  Age> 18\n\n          -  Female affiliated to French health insurance (Social Security),\n\n          -  Informed consent form signed\n\n          -  Patient with history of at least three foetal losses without any cause found\n             (chromosomal abnormalities, uterine malformations, endocrine disorders, etc.)\n\n        Exclusion criteria for females with repeated fetal losses :\n\n          -  Patient not fulfilling inclusion criteria\n\n          -  Age > 40\n\n          -  Female unable to understand benefits and risks of protocol\n\n          -  Female with history of repeated foetal losses of infectious or  endocrine origin.\n\n        Inclusion criteria for females without repeated fetal losses:\n\n          -  Age> 18\n\n          -  Female affiliated to the French health insurance (Social Security)\n\n          -  Informed consent form signed\n\n          -  Female without history of repeated foetal losses\n\n        Exclusion criteria for females without repeated fetal losses:\n\n          -  Patient not fulfilling inclusion criteria\n\n          -  Female with age above 40\n\n          -  Female unable to understand benefits and risks of protocol"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Females with medical history of repeated foetal losses and females without medical history\n        of repeated foetal losses as controls."
            }
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 29, 2011", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01690858", 
            "org_study_id": "10/6-K"
        }, 
        "intervention": {
            "arm_group_label": [
                "females with medical history of repeated foetal losses", 
                "females without medical history of repeated foetal losses"
            ], 
            "description": "blood sampling at inclusion and throughout pregnancy when pregnant", 
            "intervention_name": "blood sample", 
            "intervention_type": "Other"
        }, 
        "intervention_browse": {
            "mesh_term": "Complement System Proteins"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Foetal loss", 
            "complement", 
            "antiangiogenic factors", 
            "Repeated fetal losses"
        ], 
        "lastchanged_date": "December 7, 2012", 
        "location": [
            {
                "contact": {
                    "email": "alexandra.benachi@abc.aphp.fr", 
                    "last_name": "Alexandra BENACHI, PH", 
                    "phone": "+33 145374476"
                }, 
                "facility": {
                    "address": {
                        "city": "Clamart", 
                        "country": "France", 
                        "zip": "92141"
                    }, 
                    "name": "Antoine Beclere Hospital (AP-HP)"
                }, 
                "investigator": [
                    {
                        "last_name": "Alexandra BENACHI, PH", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Vanessa GALLOT, PH", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Sophie NEDELLEC, PH", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Fadi Fakhouri, Professor"
                }, 
                "facility": {
                    "address": {
                        "city": "Nantes", 
                        "country": "France", 
                        "zip": "44093"
                    }, 
                    "name": "CHU"
                }, 
                "investigator": {
                    "last_name": "Fadi Fakhouri, Professor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_groups": "2", 
        "official_title": "Multicentric Prospective Study of Genetic and Physiopathology Concerning Dysregulation of Complement During Repeated Fetal Abortions", 
        "overall_contact": {
            "email": "fadi.fakhouri@chu-nantes.fr", 
            "last_name": "Fadi Fakhouri, Professsor", 
            "phone": "+33 2 40 08 74 10"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "France : French  Health Products Safety Agency", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "to determine frequency of mutations of genes (membrane-cofactor protein (MCP), decay accelerating factor (DAF), ....) involved in complement activation : Profiles of these genes will be analysed in blood sample of females with medical history of repeated foetal losses and compared to those analysed in blood sample of females without medical history of repeated foetal losses.", 
            "measure": "mutations in genes coding for molecules that modulate complement activity", 
            "safety_issue": "No", 
            "time_frame": "day1 (at inclusion)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01690858"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "To assess serum levels of sFlt1 and endoglin and their link to complement activation markers in blood samples removed throughout pregnancy of females with medical history of repeated foetal losses and throughout pregnancy of females without medical history of repeated foetal losses.", 
                "measure": "serum levels of sFlt1 and endoglin and their link to complement activation markers", 
                "safety_issue": "No", 
                "time_frame": "4 weeks post pregnancy start"
            }, 
            {
                "description": "To assess serum levels of sFlt1 and endoglin and their link to complement activation markers in blood samples removed throughout pregnancy of females with medical history of repeated foetal losses and throughout pregnancy of females without medical history of repeated foetal losses.", 
                "measure": "serum levels of sFlt1 and endoglin and their link to complement activation", 
                "safety_issue": "No", 
                "time_frame": "8 weeks post pregnancy start"
            }, 
            {
                "description": "To assess serum levels of sFlt1 and endoglin and their link to complement activation markers in blood samples removed throughout pregnancy of females with medical history of repeated foetal losses and throughout pregnancy of females without medical history of repeated foetal losses.", 
                "measure": "serum levels of sFlt1 and endoglin and their link to complement activation", 
                "safety_issue": "No", 
                "time_frame": "16 weeks post pregnancy start"
            }, 
            {
                "description": "To assess serum levels of sFlt1 and endoglin and their link to complement activation markers in blood samples removed throughout pregnancy of females with medical history of repeated foetal losses and throughout pregnancy of females without medical history of repeated foetal losses.", 
                "measure": "serum levels of sFlt1 and endoglin and their link to complement activation", 
                "safety_issue": "No", 
                "time_frame": "24 weeks post pregnancy start"
            }
        ], 
        "source": "Nantes University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nantes University Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2011", 
        "study_design": "Observational Model: Case Control, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "December 2012"
    }
}